Find the latest clinical trials by condition, location & phase
Browse and search for drug information and related clinical trials
Explore a comprehensive list of organizations, including their profiles and details.
Latest updates on clinical trials, pharmaceuticals, and healthcare companies
Stay informed with timely notifications on clinical trials and research advancements.
No overview information available.
No background information available.
No indication information available.
No associated conditions information available.
DelveInsight's latest report reveals a robust pipeline with 110+ companies developing 120+ therapies for acute myeloid leukemia (AML), showing significant investment in this aggressive blood cancer.
Qurient's Adrixetinib, a selective triple kinase inhibitor, has received FDA approval for a Phase 1b IND application to treat chronic graft-versus-host disease (cGVHD).
Qurient has launched a Phase 1 clinical trial for adrixetinib (Q702) to treat relapsed/refractory acute myeloid leukemia (AML) after FDA clearance.